埃博拉出血热药物和疫苗研究开发态势分析  

R&D of medicine and vaccine for Ebola hemorrhagic fever

作　　者：刁天喜[1] 徐守军[2] 赵晓宇[1] 周巍[1] 李鹏[1] 刘术[1] 王伟[1] 

机构地区：[1]军事医学科学院卫生勤务与医学情报研究所,北京100850 [2]军事医学科学院科技部,北京100850

出　　处：《军事医学》2014年第8期569-575,共7页Military Medical Sciences

摘　　要：2014年2月暴发于西非地区的埃博拉出血热是历史上最严重的一次疫情,药物和疫苗的研究开发受到特别关注。该研究利用Thomson Reuters(汤森路透)的Cortellis数据库和既往研究积累对埃博拉出血热药物和疫苗研究开发整体态势进行分析,为正确把握开发情况提供参考。研究结果显示,疫苗、中和抗体、小分子抗病毒药物、RNA干扰技术药物和核苷酸是抗埃博拉病毒的5个重要类别,每个类别都有前景看好的品种,值得继续跟踪和关注。The outbreak of Ebola hemorrhagic fever in West Africa in February 2014 is the worst one in the history of the disease.Medicines and vaccines for Ebola have attracted special attention .This study utilizes Cortellis database of Thom-son Reuters and knowledge about Ebola virus to analyze current R＆amp;D of medicines and vaccines for Ebola in order to offer references for research and development .Study findings shows that there are mainly 5 important categories：vaccines, neu-tralizing antibodies , small-molecule anti-Ebola drugs , RNAi drugs and nucleotide drugs .In each category , there are prom-ising products under development that are worthy of attention .

关 键 词：埃博拉病毒 埃博拉出血热 药物 疫苗 

分 类 号：R512.8[医药卫生—内科学]